Resumen
Pseudomonas aeruginosa is a challenging bacterium to treat due to its intrinsic resistance to the antibiotics used most frequently in patients with community-acquired pneumonia (CAP). Data about the global burden and risk factors associated with P. aeruginosa-CAP are limited. We assessed the multinational burden and specific risk factors associated with P. aeruginosa-CAP. We enrolled 3193 patients in 54 countries with confirmed diagnosis of CAP who underwent microbiological testing at admission. Prevalence was calculated according to the identification of P. aeruginosa. Logistic regression analysis was used to identify risk factors for antibiotic-susceptible and antibiotic-resistant P. aeruginosa-CAP. The prevalence of P. aeruginosa and antibiotic-resistant P. aeruginosa-CAP was 4.2% and 2.0%, respectively. The rate of P. aeruginosa CAP in patients with prior infection/colonisation due to P. aeruginosa and at least one of the three independently associated chronic lung diseases (i.e. tracheostomy, bronchiectasis and/or very severe chronic obstructive pulmonary disease) was 67%. In contrast, the rate of P. aeruginosa-CAP was 2% in patients without prior P. aeruginosa infection/colonisation and none of the selected chronic lung diseases. The multinational prevalence of P. aeruginosa-CAP is low. The risk factors identified in this study may guide healthcare professionals in deciding empirical antibiotic coverage for CAP patients.
| Idioma original | Inglés estadounidense |
|---|---|
| - | 1701190 |
| Publicación | European Respiratory Journal |
| Volumen | 52 |
| N.º | 2 |
| DOI | |
| Estado | Indizado - 1 ago. 2018 |
| Publicado de forma externa | Sí |
Nota bibliográfica
Publisher Copyright:© ERS 2018.
Acceder al documento
Huella
Profundice en los temas de investigación de 'Burden and risk factors for Pseudomonas aeruginosa community-acquired pneumonia: A multinational point prevalence study of hospitalised patients'. En conjunto forman una huella única.Citar esto
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
En: European Respiratory Journal, Vol. 52, N.º 2, 1701190, 01.08.2018.
Producción científica: Artículo Científico › Artículo original › revisión exhaustiva
TY - JOUR
T1 - Burden and risk factors for Pseudomonas aeruginosa community-acquired pneumonia
T2 - A multinational point prevalence study of hospitalised patients
AU - Restrepo, Marcos I.
AU - Babu, Bettina L.
AU - Reyes, Luis F.
AU - Chalmers, James D.
AU - Soni, Nilam J.
AU - Sibila, Oriol
AU - Faverio, Paola
AU - Cilloniz, Catia
AU - Rodriguez-Cintron, William
AU - Aliberti, Stefano
AU - Aruj, P. K.
AU - Attorri, S.
AU - Barimboim, E.
AU - Caeiro, J. P.
AU - Garzón, M. I.
AU - Cambursano, V. H.
AU - Ceccato, A.
AU - Chertcoff, J.
AU - Lascar, F.
AU - Di Tulio, F.
AU - Díaz, A. C.
AU - de Vedia, L.
AU - Ganaha, M. C.
AU - Lambert, S.
AU - Lopardo, G.
AU - Luna, C. M.
AU - Malberti, A. G.
AU - Morcillo, N.
AU - Tartara, S.
AU - Pensotti, C.
AU - Pereyra, B.
AU - Scapellato, P. G.
AU - Stagnaro, J. P.
AU - Shah, S.
AU - Lötsch, F.
AU - Thalhammer, F.
AU - Anseeuw, K.
AU - Francois, C. A.
AU - Van Braeckel, E.
AU - Vincent, J. L.
AU - Djimon, M. Z.
AU - Bashi, J.
AU - Dodo, R.
AU - Nouér, S. A.
AU - Chipev, P.
AU - Encheva, M.
AU - Miteva, D.
AU - Petkova, D.
AU - Dodo Balkissou, A.
AU - Pefura Yone, E. W.
AU - Mbatchou Ngahane, B. H.
AU - Shen, N.
AU - Xu, J. F.
AU - Bustamante Rico, C. A.
AU - Buitrago, R.
AU - Pereira Paternina, F. J.
AU - Kayembe Ntumba, J. M.
AU - Carevic, V. V.
AU - Jakopovic, M.
AU - Jankovic, M.
AU - Matkovic, Z.
AU - Mitrecic, I.
AU - Bouchy Jacobsson, M. L.
AU - Bro Christensen, A.
AU - Heitmann Bødtger, U. C.
AU - Niels Meyer, C.
AU - Vestergaard Jensen, A.
AU - Baunbæk-Knudsen, G.
AU - Petersen, P. T.
AU - Andersen, S.
AU - Abd El-Wahhab, I. E.
AU - Elsayed Morsy, N.
AU - Shafiek, H.
AU - Sobh, E.
AU - Abdella Abdulsemed, K.
AU - Bertrand, F.
AU - Brun-Buisson, C.
AU - de Montmollin, E.
AU - Fartoukh, M.
AU - Messika, J.
AU - Tattevin, P.
AU - Khoury, A.
AU - Ebruke, B.
AU - Dreher, M.
AU - Kolditz, M.
AU - Meisinger, M.
AU - Pletz, M. W.
AU - Hagel, S.
AU - Rupp, J.
AU - Schaberg, T.
AU - Spielmanns, M.
AU - Creutz, P.
AU - Suttorp, N.
AU - Siaw-Lartey, B.
AU - Dimakou, K.
AU - Papapetrou, D.
AU - Tsigou, E.
AU - Ampazis, D.
AU - Kaimakamis, E.
AU - Bhatia, M.
AU - Dhar, R.
AU - D'Souza, G.
AU - Garg, R.
AU - Koul, P. A.
AU - Mahesh, P. A.
AU - Jayaraj, B. S.
AU - Narayan, K. V.
AU - Udnur, H. B.
AU - Krishnamurthy, S. B.
AU - Kant, S.
AU - Swarnakar, R.
AU - Limaye, S.
AU - Salvi, S.
AU - Golshani, K.
AU - Keatings, V. M.
AU - Martin-Loeches, I.
AU - Maor, Y.
AU - Strahilevitz, J.
AU - Battaglia, S.
AU - Carrabba, M.
AU - Ceriana, P.
AU - Confalonieri, M.
AU - Monforte, A. D.
AU - Del Prato, B.
AU - De Rosa, M.
AU - Fantini, R.
AU - Fiorentino, G.
AU - Gammino, M. A.
AU - Menzella, F.
AU - Milani, G.
AU - Nava, S.
AU - Palmiero, G.
AU - Petrino, R.
AU - Gabrielli, B.
AU - Rossi, P.
AU - Sorino, C.
AU - Steinhilber, G.
AU - Zanforlin, A.
AU - Franzetti, F.
AU - Carugati, M.
AU - Morosi, M.
AU - Monge, E.
AU - Carone, M.
AU - Patella, V.
AU - Scarlata, S.
AU - Comel, A.
AU - Kurahashi, K.
AU - Bacha, Z. A.
AU - Ugalde, D. B.
AU - Zuñiga, O. C.
AU - Villegas, J. F.
AU - Medenica, M.
AU - van de Garde, E. M.W.
AU - Raj Mihsra, D.
AU - Shrestha, P.
AU - Ridgeon, E.
AU - Awokola, B. I.
AU - Nwankwo, O. N.O.
AU - Olufunlola, A. B.
AU - Olumide, S.
AU - Ukwaja, K. N.
AU - Irfan, M.
AU - Minarowski, L.
AU - Szymon, S.
AU - Froes, F.
AU - Leuschner, P.
AU - Meireles, M.
AU - Ferrão, C.
AU - Neves, J.
AU - Ravara, S. B.
AU - Brocovschii, V.
AU - Ion, C.
AU - Rusu, D.
AU - Toma, C.
AU - Chirita, D.
AU - Dorobat, C. M.
AU - Birkun, A.
AU - Kaluzhenina, A.
AU - Almotairi, A.
AU - Ali Bukhary, Z. A.
AU - Edathodu, J.
AU - Fathy, A.
AU - Abdulaziz Enani, A. M.
AU - Mohamed, N. E.
AU - Memon, J. U.
AU - Bella, A.
AU - Bogdanović, N.
AU - Milenkovic, B.
AU - Pesut, D.
AU - Feldman, C.
AU - Yum, H. K.
AU - Borderìas, L.
AU - Bordon Garcia, N. M.
AU - Cabello Alarcón, H.
AU - Torres, A.
AU - Diaz-Brito, V.
AU - Casas, X.
AU - González, A. E.
AU - Fernández-Almira, M. L.
AU - Gallego, M.
AU - Gaspar-García, I.
AU - Del Castillo, J. G.
AU - Victoria, P. J.
AU - Martínez, E. L.
AU - de Molina, R. M.
AU - Marcos, P. J.
AU - Menéndez, R.
AU - Pando-Sandoval, A.
AU - Aymerich, C. P.
AU - de la Torre, A. L.
AU - García-Olivé, I.
AU - Rello, J.
AU - Moyano, S.
AU - Sanz, F.
AU - Rodrigo-Troyano, A.
AU - Solé-Violán, J.
AU - Uranga, A.
AU - van Boven, J. F.M.
AU - Torra, E. V.
AU - Pujol, J. A.
AU - Fiogbe, A. A.
AU - Yangui, F.
AU - Bilaceroglu, S.
AU - Dalar, L.
AU - Yilmaz, U.
AU - Bogomolov, A.
AU - Elahi, N.
AU - Dhasmana, D. J.
AU - Feneley, A.
AU - Ions, R.
AU - Skeemer, J.
AU - Woltmann, G.
AU - Hancock, C.
AU - Hill, A. T.
AU - Rudran, B.
AU - Ruiz-Buitrago, S.
AU - Campbell, M.
AU - Whitaker, P.
AU - Youzguin, A.
AU - Singanayagam, A.
AU - Allen, K. S.
AU - Brito, V.
AU - Dietz, J.
AU - Dysart, C. E.
AU - Kellie, S. M.
AU - Zablocki, C. J.
AU - MurphyMurphy, R. G.
AU - Franco-Sadud, R. A.
AU - Meier, G.
AU - Gaga, M.
AU - Holland, T. L.
AU - Bergin, S. P.
AU - Kheir, F.
AU - Landmeier, M.
AU - Lois, M.
AU - Nair, G. B.
AU - Patel, H.
AU - Saito, S.
AU - Noda, J.
AU - Hinojosa, C. I.
AU - Levine, S. M.
AU - Angel, L. F.
AU - Anzueto, A.
AU - Whitlow, K. S.
AU - Hipskind, J.
AU - Sukhija, K.
AU - Totten, V.
AU - Wunderink, R. G.
AU - Shah, R. D.
AU - Mateyo, K. J.
AU - Noriega, L.
AU - Alvarado, E.
AU - Aman, M.
AU - Labra, L.
N1 - Publisher Copyright: © ERS 2018.
PY - 2018/8/1
Y1 - 2018/8/1
N2 - Pseudomonas aeruginosa is a challenging bacterium to treat due to its intrinsic resistance to the antibiotics used most frequently in patients with community-acquired pneumonia (CAP). Data about the global burden and risk factors associated with P. aeruginosa-CAP are limited. We assessed the multinational burden and specific risk factors associated with P. aeruginosa-CAP. We enrolled 3193 patients in 54 countries with confirmed diagnosis of CAP who underwent microbiological testing at admission. Prevalence was calculated according to the identification of P. aeruginosa. Logistic regression analysis was used to identify risk factors for antibiotic-susceptible and antibiotic-resistant P. aeruginosa-CAP. The prevalence of P. aeruginosa and antibiotic-resistant P. aeruginosa-CAP was 4.2% and 2.0%, respectively. The rate of P. aeruginosa CAP in patients with prior infection/colonisation due to P. aeruginosa and at least one of the three independently associated chronic lung diseases (i.e. tracheostomy, bronchiectasis and/or very severe chronic obstructive pulmonary disease) was 67%. In contrast, the rate of P. aeruginosa-CAP was 2% in patients without prior P. aeruginosa infection/colonisation and none of the selected chronic lung diseases. The multinational prevalence of P. aeruginosa-CAP is low. The risk factors identified in this study may guide healthcare professionals in deciding empirical antibiotic coverage for CAP patients.
AB - Pseudomonas aeruginosa is a challenging bacterium to treat due to its intrinsic resistance to the antibiotics used most frequently in patients with community-acquired pneumonia (CAP). Data about the global burden and risk factors associated with P. aeruginosa-CAP are limited. We assessed the multinational burden and specific risk factors associated with P. aeruginosa-CAP. We enrolled 3193 patients in 54 countries with confirmed diagnosis of CAP who underwent microbiological testing at admission. Prevalence was calculated according to the identification of P. aeruginosa. Logistic regression analysis was used to identify risk factors for antibiotic-susceptible and antibiotic-resistant P. aeruginosa-CAP. The prevalence of P. aeruginosa and antibiotic-resistant P. aeruginosa-CAP was 4.2% and 2.0%, respectively. The rate of P. aeruginosa CAP in patients with prior infection/colonisation due to P. aeruginosa and at least one of the three independently associated chronic lung diseases (i.e. tracheostomy, bronchiectasis and/or very severe chronic obstructive pulmonary disease) was 67%. In contrast, the rate of P. aeruginosa-CAP was 2% in patients without prior P. aeruginosa infection/colonisation and none of the selected chronic lung diseases. The multinational prevalence of P. aeruginosa-CAP is low. The risk factors identified in this study may guide healthcare professionals in deciding empirical antibiotic coverage for CAP patients.
UR - http://www.scopus.com/inward/record.url?scp=85051459272&partnerID=8YFLogxK
U2 - 10.1183/13993003.01190-2017
DO - 10.1183/13993003.01190-2017
M3 - Original Article
C2 - 29976651
AN - SCOPUS:85051459272
SN - 0903-1936
VL - 52
JO - European Respiratory Journal
JF - European Respiratory Journal
IS - 2
M1 - 1701190
ER -